Illumina, Inc.
NASDAQ:ILMNMedical - Diagnostics & Research
+$1.95 today
- Market cap
- $31.75B
- Beta
- 1.49
- P/E (TTM)
- 28.9
- EPS (TTM)
- $5.58
Volume 1.63M
Average 1.65M
ILMN Common Stock Issued
Cash raised by issuing new shares.
Illumina, Inc.NASDAQ: ILMN
Common Stock Issued · Q2 FY2026 · quarter ended Jun 2026
Common stock issued turns negative
Q2 FY2026 common stock issued was -$24M, compared with $1M a year earlier. Trailing-twelve-month common stock issued was $16M. Over 3 fiscal years it compounded at -11.3% a year.
Context
- Common stock issued amounted to 1.0% of revenue in FY2025, down 0.3 pp from a year earlier.
- Common stock issued increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly common stock issued holds near -$24M or moves back toward the trailing-twelve-month quarterly average of $4M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Common Stock Issued history
USD · from the cash flow
- Latest · FY2025
- 44M USD
- Year-over-year change
- -21.4%
- 4-year CAGR
- -7.5%
| Period | Period end | Common Stock Issued | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-28 | 44M | -21.4% |
| FY2024 | 2024-12-29 | 56M | -16.4% |
| FY2023 | 2023-12-31 | 67M | +6.3% |
| FY2022 | 2023-01-01 | 63M | +5.0% |
| FY2021 | 2022-01-02 | 60M | — |
Common Stock Issued vs competitors
How ILMN compares with its peers on the latest reported figures
- ILMN's LTM Jun 2026 common stock issued of $16M is the 6th largest of the 11 companies compared; the peer median is $11.2M.
- Its year-over-year change of -66.7% is the 7th highest of 8, against a peer median of +20.7%.
- Common stock issued amounts to 0.4% of revenue for ILMN, versus a peer median of 2.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
BLLNBillionToOne, Inc. | LTM Jun 2026 | $297.55M | — | — | 74.9% |
| LTM Mar 2026 | $132.59M | +16.1% | — | 205.5% | |
| LTM Sep 2026 | $70.38M | +443.1% | — | 5.5% | |
| LTM Jun 2026 | $55.4M | +113.9% | -52.8% | 2.0% | |
| LTM Mar 2026 | $16.25M | — | — | 20.0% | |
| LTM Jun 2026 | $16M | -66.7% | -11.3% | 0.4% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | $13.44M | -121.6% | -36.1% | 3.0% |
| LTM Jun 2026 | $6.15M | +20.7% | -31.6% | 1.0% | |
| LTM Jun 2026 | $3.88M | +138.2% | -57.6% | 0.5% | |
| LTM Mar 2026 | $3.3M | — | — | 0.4% | |
| LTM Mar 2026 | $2.91M | +4.9% | -32.7% | 1.8% | |
| Peer median (excluding ILMN) | $11.2M | +20.7% | -36.1% | 2.5% | |
Competitors are the stored peer set for ILMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Jan 2022 | FY2022 Jan 2023 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 762M | (4.4B) | (1.16B) | (1.22B) | 850M |
| Depreciation & Amortization | 251M | 394M | 432M | 354M | 270M |
| Deferred Income Tax | (76M) | (23M) | (33M) | (112M) | 119M |
| Stock-Based Compensation | 754M | 366M | 380M | 370M | 275M |
| Change in Working Capital | (152M) | 204M | (90M) | (483M) | (153M) |
| Accounts Receivables | (164M) | (12M) | (40M) | (25M) | (108M) |
| Inventory | (58M) | (135M) | (20M) | 19M | (17M) |
| Accounts Payables | 60M | (38M) | (44M) | (4M) | 2M |
| Other Working Capital | 10M | 389M | 14M | (473M) | (30M) |
| Other Non-Cash Items | (994M) | 3.86B | 950M | 1.93B | (282M) |
| Operating Cash Flow | 545M | 392M | 478M | 837M | 1.08B |
| Capital Expenditures | (208M) | (286M) | (195M) | (128M) | (148M) |
| Acquisitions (Net) | (2.44B) | (265M) | (29M) | 2M | (10M) |
| Purchases of Investments | (77M) | (40M) | (6M) | (52M) | 0 |
| Sales of Investments | 1.66B | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | (1M) | 0 | 103M |
| Investing Cash Flow | (1.07B) | (591M) | (231M) | (178M) | (55M) |
| Debt Repayment | 471M | 991M | (1.24B) | 491M | (5M) |
| Common Stock Issued | 60M | 63M | 67M | 56M | 44M |
| Common Stock Repurchased | 0 | 0 | 0 | (116M) | (742M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (582M) | (54M) | (42M) | (1B) | (41M) |
| Financing Cash Flow | (51M) | 1B | (1.21B) | (570M) | (744M) |
| Effect of Forex Changes | (3M) | (22M) | 0 | (10M) | 11M |
| Net Change in Cash | (578M) | 779M | (963M) | 79M | 291M |
| Free Cash Flow | 337M | 106M | 282M | 709M | 931M |
Illumina, Inc.
NASDAQ:ILMN
Intrinsic Alpha fair value
Locked
Current Price
$210.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.